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OBJECTIVES: Previous studies have established that etanercept
is cost-effective when used for the treatment of rheumatoid
arthritis (RA) following the failure of 2 DMARD therapies.
This analysis explores the use of etanercept after the failure
of a previous anti-tumor necrosis factor (anti-TNF) agent.
METHODS: A sequential Markov model was developed to
predict the costs and health outcomes associated with different
treatments for patients with RA in the UK. The model estimated
the cost-effectiveness of sequential anti-TNF therapies when
compared against a sequence containing no anti-TNF treatments
(i.e. solely DMARD therapies). In a separate analysis, etanercept
was compared against rituximab after the failure of a previous
anti-TNF. For each treatment, the initial, medium-term and long-
term effects on the Health Assessment Questionnaire (HAQ)
score were calculated. HAQ scores at each time period deter-
mined each patient’s utility (QALYs), resource use and mortality.
Effectiveness data (HAQ progression, serious adverse events and
mortality) were derived from the results from trials and pub-
lished literature. Various scenarios were assessed using different
interpretations of effectiveness data for sequential use of anti-
TNFs. Utility scores were converted from HAQ data using the
EQ-5D. Cost data were drawn from established national data-
bases. RESULTS: Patients who received two successive anti-TNF
therapies gained between 0.63 (when the initial HAQ change for
etanercept was assumed to be 0.51) and 0.76 (when the initial
HAQ change was assumed to be 0.40) additional QALYs com-
pared to the DMARD-only cohort. The incremental cost varied
between £11,300 and £13,600, resulting in the incremental cost-
effectiveness ratios (ICER) ranging between £17,916 and
£20,479. When etanercept was compared against rituximab after
the failure of another anti-TNF, the ICER ranged between £7290
and £9031. CONCLUSIONS: This study has demonstrated that
etanercept is a cost-effective treatment option for patients with
rheumatoid arthritis, even when it is used sequentially with other
anti-TNF agents.
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OBJECTIVES: To evaluate the cost-effectiveness of rituximab
compared with TNF inhibitors for the treatment of RA patients
following the failure of 2 DMARDs and 1 TNF inhibitor in
Polish setting. METHODS: A cost-utility approach was adopted,
evaluating the total direct National Health Fund costs and
QALYs. Baseline patient characteristics were based on the
REFLEX and DANCER phase III trials. A micro-simulation
model of 50 000 RA patients estimated lifetime Health Assess-
ment Questionnaire (HAQ) progression, QALYs and direct costs.
The starting time-point of the model was the failure of two
previous DMARDs. Two treatment options were compared.
Upon treatment failure it was assumed patients would follow an
identical lifetime treatment strategy consisting of: TRDM—
inﬂiximab, rituximab, leﬂunomide and palliative care or TTDM
—inﬂiximab, etanercept, leﬂunomide and palliative care. Ritux-
imab was assumed to be administered every 9 months to
responding patients. ACR response rates were taken from the
phase III RCTs and adjusted for placebo response. The initial
HAQ drop by ACR category and longterm HAQ progression
ware taken from the published literature. RESULTS: Annual
drug acquisition and administration costs were lower for TRDM
compared to TTDM. Discounted total lifetime direct NHF costs
were 216,460 pln and 233,734 pln for TRDM and TTDM
groups respectively. Total QALYs were 29,952 and 25,854 for
TRDM and TTDM, respectively. TRDM is a dominant therapy
over TTDM. CONCLUSIONS: The model predicted that
TRDM dominated options for RA patients who have failed
DMARD therapy, with higher estimated QALYs and lower NHF
costs. The results will be different when different TNF inhibitors
will be taken into account.
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OBJECTIVES: Recombinant human bone morphogenetic
protein (rhBMP2) is a novel biologic therapy that promotes
bone growth at the fracture site. We analyzed the cost-
effectiveness of rhBMP-2 in open tibia fractures in The Neth-
erlands. METHODS: An economic model comparing rhBMP-2
plus standard of care -consisting of soft tissue management and
intramedullary nailing- with standard of care alone. Clinical
data were drawn from the BMP-2 Evaluation for Surgery in
Tibial Trauma (BESTT) trial and treatment costs were taken
from Dutch national sources. Total costs were calculated as
direct plus indirect costs. Direct costs consisted of drug costs
and cost for complications. Indirect costs were calculated as
lost productivity times average annual salaries. Utility weights
were assigned to different grades (Gustillo IIIA and B) of open
tibia fractures to estimate the difference in quality-adjusted-life-
expectancy. We performed the analysis from payer’s and soci-
etal perspectives for a one-year time-horizon. RESULTS: In The
Netherlands, use of rhBMP-2 for grade III open tibia fractures
resulted in an incremental cost of €1,935 per patient and in
incremental cost-effectiveness ratio (ICER) of €27,587/QALY.
When indirect costs were included, rhBMP-2 treatment for
grade III open tibia fractures resulted in an incremental cost of
€400 per patient and an ICER of €5,708/QALY. CONCLU-
SIONS: From a payer’s perspective, rhBMP-2 is a cost-effective
treatment option in grade III open tibia fractures for the Dutch
health care systems.
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OBJECTIVES: The aim of this analysis was to evaluate cost
consequences of rituximab (RTX) treatment in rheumatoid
arthritis (RA) from the payer perspective, in a phase IV open-
label study conducted by Clalit Health Services, the largest
Israeli HMO, in collaboration with Roche Pharmaceuticals.
METHODS: Patients with prior inadequate response to disease-
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